brolucizumab
UkraineDrugs containing this active substance
-
The drug is intended for the treatment of adult patients with neovascular (exudative) age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME).
Form: solution for injection
Active substance Dosage brolucizumab 120 mg/ml ATC: S01LA06
Manufacturer: Novartis Manufacturing NV (batch release)